Summary.-Male DBA2 mice were given 106 P-388 leukaemic cells i.p. and cimetidine (CMT) at 100 mg/kg 1 day for 10 days, or as a single 100mg/kg injection 30 min before cyclophosphamide (CTX). CMT significantly prolonged the survival of groups of mice receiving 50, 100 and 200 mg/kg of CTX 3 days after tumour inoculation.
Median survival increased by 5-5 days (P <0-05), 10 days (P <0.05) and 13 days (P < 0.05) respectively. The addition of CMT had the effect of roughly doubling the CTX dose, without increasing the lethality. CMT produced the only long-term survival seen in the study (1-2/10) CMT alone had no apparent antitumour activity. CMT significantly prolonged mean pentobarbital sleep to 28-6-60 min vs only 10 min for phenobarbital treated mice. Both CMT regimens increased the plasma concentration time products for CTX-induced metabolites (NBP) by about 1-3 fold (in contrast to a 33% reduction with phenobarbital). On average the single-dose CMT regimen produced the greatest effect on survival, on pentobarbital sleep duration and on total NBP reactive species. Probable mechanisms for the CMT-CTX interaction include competitive microsomal enzyme inhibition and/or acutely depressed hepatic blood flow. Caution should be used in combining CMT with full doses of CTX and any other highly metabolized antineoplastic agents in man.
CYCLOPHOSPHAMIDE (CTX) is a clinically important anticancer drug which must be metabolized in vivo to its alkylating species to show antitumour activity in animals and man (Brock et al., 1971; Sladek, 1972) . The initial step of the complex metabolic process involves enzymatic hydroxylation in the 4 position of the oxazophosphorine ring, and is mediated by mixed-function oxygenase; microsomal enzymes concentrated in the mammalian liver. A variety of other drugs used clinically may interact with these enzyme systems and thereby alter the metabolic activation and antitumour effectiveness of CTX (Hart & Adamson, 1] 
969).
Cimetidine (CMT) is a blocker of the H2 histamine receptor and is used in the treatment of ulcer disease (Henn et al., 1975) . Recently, CMT has been shown to depress the clearance of a number of microsomally metabolized drugs in rodents (Desmond et al., 1980a; Pelkonen & Puurunen, 1980) and in man (Desmond et al., 1980b; Klotz et al., 1979; Serlin et al., 1979; Jackson et al., 1981) .
Because CMT can alter drug metabolism and is commonly used in cancer patients, we studied the possibility of interaction between CMT and CTX in leukaemic mice. Our results show significant cimetidineinduced enhancement of both the antitumour effects of CTX and the total of alkylating metabolites produced by a single large CTX dose.
METHODS
Mice.--Six to 8-week-old male DBA2 mice weighing , 28 g were used in all experiments. For survival studies mice were divided into treatment groups of 10 and housed 5 per cage on standard wood-chip bedding, and were given acid drinking water anid food ad libitum. Animals were acclimilatized at least 2 weeks before study.
Tumour. P-388 leukaemic cells were collected fresh from the ascitic fluid of 3-4 pi:etreated inice. The (Venditti, 1975 Survival N as assessed by observing for death at 12 h intervals. Survival wvas statistically analysed by computer., primarily using a generalized Wilcoxon test (Gehan, 1965) . In some instances the logrank test was added for comparison of survival patterns, since the Wilcoxon test censors data in favour of early survival differences, wNhereas the logrank method is wAeighted in favour of detecting differences in long-term survival (Mantel. 1966). (Cyclophosphamnide alkylating mnetabolites by NBP Assay. Four groups of animals (n = 40 each) were used to study the production of alkylating metabolites of CTX after i.p. injection of 200 mg/kg. This high dose was historical convention and was necessitated by the sensitivity limits of the assay. This dose is close to the LD10 (in BDF1 mice) of -250-300 mg/kg (Hill, 1975) . At serial times after CTX, groups of 4 mice were lightly anaesthetized with ether and the total available blood collected by cardiac puncture into iced heparinized centrifuge tubes. The pooled plasma (-.5 ml) w-as separated by centrifugation at 2000 rev/min for 10 min. and stored frozen at -20°C for analysis later on the day of collection. 
RESULTS
The addition of CMT to all 3 CTX doses (50, 1]00 and 200 mg/kg) significantly prolonged the survival of the leukaemic mice, (Fig. I and Table I ). Median survival increased by 5-5 days ((P < 0.005) 7 0 days (P < 0 05) and by 13-0 days (P < 0 05) for the 3 CTX doses respectively. There was no apparent antitumour effect for CMT alone at 100 mg/kg i.p. for 10 days. Survival was identical to a saline-treated group (median survival 13 days). Longterm survival was produced only by the addition of CMT, and an advantage was seen for the single pre-CTX 100 mg/kg CMT administration. This was significantly better than 10 days of CMT treatment at this CTX dose level (P = 0'0001, Fig. 2 ).
At the highest CTX dose (200 mg/kg i.p.) early treatment deaths cancelled CMT effects on median survival. None the less, long-term survival was still produced only in groups receiving concomitant CMT: 10% long-term survival in the single-dose CMT group and 20% long-term survival in the 10-day CMT group. The addition of oral phenobarbital at this high CTX dose did not alter survival. The further addition of CMT to phenobarbital and CTX tended to increase median survival (from 18 days to 28 days) but! this difference was not statistically significant.
Thus the most effective treatments in this study were 100 mg/kg CTX plus the single CMT injection (better survival than with 200 mg/kg CTX alone; P < 0-02 Wilcoxon, < 0*05 logrank Fig. 3 ) and the 200 mg/kg CTX plus either single-dose or 10-day CMT; the latter producing the highest long term survival rate (Fig.  IC') (Shearer et al., 1972) and T-mediated cytolysis (Plaut et al., 1973) . Recently, CMT has been shown to prevent the metastatic spread of 3LL adenocarcinoma and to extend survival in mice (Osband et al., 1981) . Inactivation of suppressor cells by CMT indicated a direct immunological tumoricidal role for the drug. Simultaneously Gifford et al. (1981) showed that CMT significantly reduces tumour formation and increases the survival of mice given the EL4 ascites lymphoma or the Mc43 fibrosarcoma. No direct in vitro cytoxicity of CMT was seen. This is consistent with our conclusion that CMT alone had no antitumour activitv.
The most effective immunostimulative CMT dose in Gifford's study (100 mg/kg/ day orally) is identical to the i.p. dose used in the present report. While this dose is much larger than CMT doses clinically recommended in man (up to 20 mg/ kg/day), peak murine plasma levels from this dose are comparable to levels obtained in man following standard doses (Gifford et al., 1981) . Thus, the CMT dose used in the current study should be of biological significance in man.
In addition to the direct haemotological and immunological effects of CMT, the drug also depresses the clearance of a variety of other drugs whose elimination depends on microsomal metabolism. The list of drugs so effected includes the sedatives chlordiazepoxide (Desmond et al., 1980b) and diazepam (Klotz et al., 1979) the oral anticoagulant warfarin (Serlin et al., 1979) the methylxanthines caffeine (Desmond et al., 1980a) and theophylline, (Campbell et al., 1981; Jackson et al., 1981) as well as the hepatic-clearance indicator drugs, antipyrine (Klotz et al., 1979) and aminopyrine (Desmond et al., 1980a) . Furthermore, Pelkonen & Puurunen (1980) found that CMT pretreatment in rats caused significant prolongation of hexobarbital sleep and inhibition of aminopyrine N-demethylation without altering benzo(a)pyrene hydroxylation. In addition pretreatment did not induce hepatic drug metabolism. This pattern is consistent wTith non-specific CMT inhibition of the cytochrome microsomal enzyme systems including the P-448 and P-450 fractions. Spectral analysis indicates a Type II inhibitory pattern for CMT (believed to be a general property of compounds with a "sterically-accessible" nitrogen atom including imidazoles like CMT [Mailman et al., 19741) .
Cyclophosphamide is an antitumour drug which exerts its cytoxic effects via the generatioin of alkylating metabolites, principally phosphoramide mustard (Struck et al., 1975) . Activation of the drug is initiated by 4-hydroxylation, process predominantly due to hepatic microsomal mixed-function oxidases (Cohen & Jao, 1970) . Phenobarbital, a known inducer of diverse hepatic microsomal activities (including P-450), has demonstrated no significant CTX interactions in man (Jao et al., 1972 ). Yet in experimental animals in this study and others (Alberts et al., 1976; the addition of this enzyme inducer markedly reduces the total amount of alkylating metabolites from CTX, and its antitumour effects. It should be borne in mind, however, that phenobarbital administration also increases hepatic size and blood flow (Yates et al., 1978) and bile flow (Klaassen, 1] 969). Conversely, experimental microsomal enzyme inhibitors such as SKF-525a (diethylaminoethyldiphenyl valerate) depress hepatic blood flow (Hakim & Fujimoto, 1971 ) and can reverse phenobarbital induction and restore CTX antitumour activity (Alberts et al., 1976) . When used alone, SKF-525a reduced CTX lethality in animals without altering its antitumour effectiveness (Hart & Adamson, 1969) . This inhibitor can also prolong the half-life of CTX in mice (Bus et al., 1973) an effect identical to the CMT-CTX interaction in the present study. CMT also similarly reduiced CTX lethality in this study while substantially enhancing both early and late tumour suirvival.
Thus we have deinonstrated consisteint CMT-induced enhancement of t,he antitumour effect of CTX in mice. CMT also significantly prolonged phenobarbital sleep, as in the findings of Pelkonen & Puurunen (1980) . We were not, able to detect a direct, antitumour effect of CMT in the P-388 leukaemia system. OIn average the addition of CMT as a 10-day i.p. load had the survival prolongation effect of roughly doubling the CTX dose (Table I) . Also CMT inclusion produced the only long-term survival. In this respect the 1 0-day CMT load did not dramatically increase survival over a single CMT injection 30 min before CTX. Similarly a single CMT injection produced the largest amount of NBP alkylating species (Table  II) , and the greatest prolongation of pentobarbital sleep. A significant CMT effect on liver size or total microsomal enzyme mass is not consistent with these results. At least two other reasonable explanations remain for the augmented CTX effects seen in this study: (1) a competitive alteration or blockade of substrate (CTX) sites on hepatic P-450 microsomal enzymes and (2) a significant CMT-induced reduction in liver blood flow, slowing the hepatic extraction of CTX A reduction in liver blood flow has been described for the other classic enzyme inhibitor SKF-525a in animals (Marchand & Brodeur, 1970) and in man; CMT has been shown to depress liver blood flow by up to 25% after acute administration and by 3300 followving chronic oral administration (Feely et al., 1981) .
The results of the NBP-CTX assays are difficult to assess since the assay is not specific for cvtotoxic CTX metabolites. Thus inactive as well as active metabolites and parent drug will be quantified. None the less, our analysis demonstrated prolonged retention of NBP-reactive species in CMT-treated mice (Figs 4 & 5) . In additioni phenobarbital depressed the formation of total NBP-reactive species by about one-third (Table II) . This is consistent with pharmacokinetic results uising a more specific NPB-reactive, thinlayer chromatography in which a 270% reduction in the AUC for phosphoramide mustard was obtained following the combination of CTX with phenobarbital (Alberts et al., 1978) . The more rapid CTX decay in the presence of phenobarbital had also been described earlier (Field et al., 1972; Bus et al., 1973) . It is possible that CMT might have even greater effects on orally administered CTX, for which hepatic extraction is significant following absorption. In this regard CMT has recently been shown to substantially increase the bioavailability of oral propranolol, another highly extracted drug (Heagerty et al., 198 1) .
The metabolism of a number of other clinically used anticancer drugs is mediated to some degree by microsomal enzymes. These include procarbazine, dacarbazine, doxorubicin, hexamethylmelamine and the nitrosoureas. For one such compound, the nitrosourea carmustine (BCNU) a similar pattern to CTX is emerging: phenobarbital pretreatment in rats destroyed the antitimour activity of BCNU (Levin et al., 1979) while concurrent CMT markedly enhanced BCNU-induced marrow depression in a single patient (Selker et al., 1978) . It should also be borne in mind, however, that drug metabolism and microsomal enzyme activity may be inhibited by the presence of tumour (Rosso et al., 1971) or by the antitumour drug itself (e.g. CTX in Marinello et al., 1981) .
In conclusion we have demonstrated that CMT induces (1) statistically significant augmentation of CTX antitumour effects in leukaemic mice and (2) substantial increases in NBP alkylating species following a large CTX dose. It is possible that similar CMT-induced CTX augmentation may be seen in man. Thus, until more definitive studies are completed, caution should be exercised whenever cimetidine is combined with full doses of CTX or any other microsomallv metabolized antineoplastic drug.
